AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2024
Oct 4, 2024
34564_dirs_2024-10-03_fd54095e-3511-4c34-9047-7a45194fed75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2024-09-17
Reporting Person: Wiley Matthew T. (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-17 | Common Stock | A | 21250 | — | Acquired | 25283 | Direct |
| 2024-10-03 | Common Stock | S | 6272 | $0.55 | Disposed | 19011 | Direct |
Footnotes
F1: The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.